Imipramine

Limits on what this shows

• Key negative/null findings: A separate, title-level-only source (Reus GZ, Stringari RB, Rezin GT, et al, "Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain," J Neural Transm 2011, PMID 21953515) could not be read beyond its title and author list in this review (see tooling disclosure); its direction of effect in brain tissue is not confirmed here and is not used to support or contradict this entry.
• At-risk subgroups: Not established as a safety concern, since both drug-specific findings run in the enhancing direction in liver tissue.
• Counter-evidence on record: None identified contradicting the enhancing direction in liver specifically; this entry shares its evidentiary core in part with ATP production below, see the Overlap map.

Regulatory status

Not addressed in either FDA label.

Population evidence

Katyare SS, Rajan RR, "Enhanced oxidative phosphorylation in rat liver mitochondria following prolonged in vivo treatment with imipramine," Br J Pharmacol 1988;95(3):914-922, PMID 3207998 (Tier B, rat, one and two weeks of treatment). State 3 respiration rates increased with all substrates tested as early as one week and sustained through two weeks; intramitochondrial cytochrome aa3 and c-plus-c1 content increased selectively, without changes in total liver protein, mitochondrial protein, or mitochondrial yield, leading the authors to propose altered mitochondrial membrane lipid milieu and fluidity as the mechanism. Liu X, Hou S, Xiang R, Hu C, Chen Z, Li N, Yan H, Yu X, Li X, Chi Y, Yang J, "Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis," Metabolism 2022, DOI 10.1016/j.metabol.2022.155292, PMID 35995281 (Tier B, mouse NAFLD model). Imipramine activated the FAM3A-FOXA2-CPT2 pathway; CPT2 (carnitine palmitoyltransferase 2) is a mitochondrial inner-membrane enzyme controlling fatty-acid entry into beta-oxidation, so pathway activation indicates enhanced mitochondrial fatty-acid oxidative capacity, consistent in direction with the Katyare 1988 finding despite the 34-year gap and different disease model. The full abstract text for this paper could not be retrieved in this review; the direction stated here rests on the paper's title and the named pathway's known physiology, disclosed as such.

Mechanism

Enhanced oxidative phosphorylation and mitochondrial fatty-acid oxidation capacity in liver, via altered membrane lipid milieu (Katyare 1988) and FAM3A-FOXA2-CPT2 pathway activation (Liu 2022); both point toward increased, not decreased, mitochondrial functional capacity in this tissue.

Counter-evidence held on record

This is real, drug-specific, direction-consistent animal data limited to liver tissue; it must never be presented as a confirmed human mitochondrial benefit, and never used to suggest imipramine should be taken for mitochondrial support. The brain-specific findings from the same Brazilian research group's earlier nortriptyline work (batch B007) do not automatically carry over to imipramine and are not assumed here.

Limits on what this shows

• Key negative/null findings: Superoxide dismutase activity was unchanged by imipramine alone in the Duda 2016 study, a real null finding within an otherwise pro-oxidant-leaning result set, recorded here rather than omitted.
• At-risk subgroups: Not established in humans; this is a single rat-liver study.
• Counter-evidence on record: The same study's own finding that catalase and glutathione peroxidase rose substantially is itself a form of counter-evidence against reading this as unopposed oxidative damage; the net physiological consequence in liver was not resolved by this study's design.

Regulatory status

Not addressed in either FDA label.

Population evidence

Duda W, Curzytek K, Kubera M, Iciek M, Kowalczyk-Pachel D, Bilska-Wilkosz A, Lorenc-Koci E, Leskiewicz M, Basta-Kaim A, Budziszewska B, Regulska M, Slusarczyk J, Gruca P, Papp M, Maes MHJ, Lason W, Antkiewicz-Michaluk L, "The Effect of Chronic Mild Stress and Imipramine on the Markers of Oxidative Stress and Antioxidant System in Rat Liver," Neurotoxicity Research 2016;30(2):173-184, PMID 26961706 (Tier B, male Wistar rats, 7-week chronic mild stress protocol plus 5 weeks imipramine, five groups including a non-stressed imipramine-alone arm). In non-stressed rats, imipramine alone increased reactive oxygen species (41.5 percent), malondialdehyde (67 percent), non-protein sulfhydryl groups (25.3 percent), and sulfane sulfur, while also elevating glutathione peroxidase (62 percent) and catalase (77 percent) activity; superoxide dismutase was unchanged. The authors concluded chronic-mild-stress-induced hepatic oxidative stress was "not prevented by" imipramine and that liver oxidative stress and antioxidant system changes are "not directly connected with" the drug's antidepressant effect, describing imipramine's own liver effect as a "pro-oxidant action."

Mechanism

Not fully established; the authors' own framing is descriptive (a pro-oxidant action with compensatory antioxidant-enzyme upregulation) rather than mechanistic. A separate, title-level-only source found long-term imipramine increased nitrate levels in rat hypothalamus, consistent in direction with a nitrosative-stress signal, but this review could not retrieve that paper's full text (see tooling disclosure, and it is not otherwise relied upon here).

Counter-evidence held on record

Do not present imipramine as either a general pro-oxidant or a general antioxidant; the single drug-specific study located shows both a pro-oxidant marker increase and a compensatory antioxidant-enzyme increase in rat liver, with no human data and no resolved net effect. This entry sits in tension with the enhancing direction found under Mitochondrial burden above; both are disclosed rather than reconciled into a single narrative, and the Overlap map below notes where they might otherwise be double-counted.

Limits on what this shows

• Key negative/null findings: Brain copper (hippocampus and cerebellum) was explicitly unchanged with imipramine, a real null finding recorded in the same paper as the serum result and disclosed here alongside it rather than omitted.
• At-risk subgroups: Cannot be specified; no human population data exists to identify an at-risk subgroup for this finding.
• Counter-evidence on record: The brain-copper null finding in the same study is itself the recorded counter-evidence against generalizing this to a whole-body or CNS copper-depletion claim; only serum copper moved.

Regulatory status

Not addressed in either FDA label.

Population evidence

Schlegel-Zawadzka M, Nowak G, "Alterations in serum and brain trace element levels after antidepressant treatment. Part II. Copper," Biol Trace Elem Res 2000, DOI 10.1385/BTER:73:1:37, PMID 10949967 (Tier B, rat, chronic imipramine, citalopram, and electroconvulsive shock). This paper is confirmed drug-specific to imipramine in its own primary text, resolving the exact question this dossier's brief raised: a nortriptyline dossier repair pass (batch B007) had found the same paper tested imipramine and citalopram but not nortriptyline, and that is independently verified here. Chronic imipramine (and separately citalopram) significantly decreased serum copper by approximately 14 percent; chronic treatment with both drugs did not alter brain copper level in hippocampus or cerebellum. Electroconvulsive shock produced the opposite effect on brain copper, a significant 36 percent increase in hippocampus and 16 percent increase in cerebellum, a different mechanism from the pharmacological treatments.

Mechanism

Not established by the source; the authors report the serum decrease without proposing a specific absorption, chelation, or renal-handling mechanism. No absorption-interference or chelation mechanism connecting imipramine to copper is documented in either FDA label.

Counter-evidence held on record

This is a real, drug-specific, statistically significant animal finding, but it is a single rat study with no human replication and no confirmed mechanism; it must not be presented as an established human copper-depletion effect, and no supplement dose is supported by this entry.

Limits on what this shows

• Key negative/null findings: No pre-treatment or drug-naive comparator arm is described in the located abstract; this is precisely the ambiguity that caps this entry at yellow rather than orange, per Hard Rule 3 (an unfalsifiable or under-specified causal claim cannot be graded above a cautious yellow) and Hard Rule 6 (confounding presumed until excluded).
• At-risk subgroups: Panic disorder patients on imipramine who develop jitteriness, the population actually studied; not established as generalizable to other indications or to imipramine's enuresis use in children.
• Counter-evidence on record: The study's own small scope and cross-sectional design are the limiting considerations recorded here; no independent replication or contradicting study was located.

Regulatory status

Not addressed in either FDA label; the label's hematologic adverse-reaction list (bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia) does not include anemia or iron-related findings, a genuine null finding recorded here rather than silently omitted.

Population evidence

Yeragani VK, Pohl R, Baton R, Ramesh C, Weinberg P, "Imipramine-induced jitteriness and decreased serum iron levels," Neuropsychobiology 1992, DOI 10.1159/000118801, PMID 1603294 (Tier A, human, panic disorder patients treated with imipramine). Patients who developed jitteriness on imipramine had significantly lower serum iron than those without jitteriness (p = 0.01). The abstract locatable in this review does not state whether serum iron was measured before treatment began or only during the jitteriness episode, so whether this reflects a pre-existing vulnerability marker or a drug-induced decline could not be resolved in this review.

Mechanism

Not established. No absorption-interference, chelation, or renal-handling mechanism connecting imipramine to iron status is documented in the FDA label or in any other source located in this review.

Counter-evidence held on record

Do not present this as "imipramine depletes iron." The single located study cannot establish that direction of causality, and it studied a specific side effect (jitteriness) in a specific population (panic disorder), not iron status in imipramine users generally.

Limits on what this shows

• Key negative/null findings: Cussotto S et al, "Unravelling the antimicrobial action of antidepressants on gut commensal microbes," Sci Rep 2020, DOI 10.1038/s41598-020-74934-9 (Tier C for imipramine) directly tested phenelzine, venlafaxine, desipramine, bupropion, aripiprazole, and (S)-citalopram against gut bacterial strains, finding desipramine and aripiprazole most antimicrobially potent; imipramine itself was not tested in this paper. The same paper cites, without imipramine specifically appearing in its own methods, prior literature reporting imipramine "inhibited the growth of E. coli and Yersinia enterocolitica." This review attempted to trace that citation to its primary source across PubMed, Crossref, and OpenAlex search queries and could not locate or independently verify it within this session's available access (see tooling disclosure); it is disclosed here as an unverified secondhand claim, not cited as evidence, consistent with the prohibition on citing a source not actually opened.
• At-risk subgroups: Not established as a safety concern in the direction found; the Chen 2026 study describes a therapeutic mechanism, not a disruption risk.
• Counter-evidence on record: The unverified antimicrobial citation described above is recorded explicitly as a gap, not folded silently into either a supporting or contradicting position for this entry.

Regulatory status

Not addressed in either FDA label.

Population evidence

Chen Y, Lan Y, Yi J, Qi X, Liu L, Liu S, Xu X, Liu H, He Y, He B, Ma X, Lu M, Liang S, "The gut microbiota mediates the antidepressant effects of imipramine: Evidence from fecal microbiota transplantation and prebiotic inulin intervention," Psychopharmacology 2026, DOI 10.1007/s00213-026-07135-3, PMID 42530642 (Tier B, mouse, chronic unpredictable mild stress model, 16S rRNA sequencing, FMT and inulin intervention arms). Imipramine treatment significantly increased the relative abundance of putative Akkermansia muciniphila and Lactobacillus reuteri, both correlating with behavioral improvement; the authors conclude imipramine "partially exerts its antidepressant activity through microbiota modulation." No reduction in overall microbial diversity or abundance was reported for imipramine in this study.

Mechanism

Selective cultivation of specific beneficial commensal taxa (Step 2, mechanism class G, in the protective rather than disruptive direction), not broad antimicrobial disruption of the gut community.

Counter-evidence held on record

This is mouse data from a single research group; it must not be presented as confirmed human microbiome benefit. If the unverified antimicrobial claim described above is ever confirmed against a primary source, this entry should be revisited, since it could point toward a real disruption risk that this review could not confirm either way.

Limits on what this shows

• Key negative/null findings: No source located contradicts this inference, but none confirms it directly either; this absence of any direct ATP assay, despite imipramine's nearly 70-year publication history, is itself recorded as a genuine and somewhat surprising literature gap.
• At-risk subgroups: Cannot be specified; no direct human or animal ATP measurement exists for this drug.
• Counter-evidence on record: None identified; the entry is explicitly labeled as extrapolation rather than direct evidence.

Regulatory status

Not addressed in either FDA label.

Population evidence

A dedicated PubMed search combining imipramine with ATP synthase, ATP content, or ATP synthesis returned ten visible results on its first page, none directly measuring ATP in imipramine-exposed tissue (see Sources for the full result list, including one incidentally relevant hepatic-steatosis pathway paper, Liu 2022, already counted under Mitochondrial burden). The Katyare 1988 finding of increased state 3 respiration (the ADP-driven, ATP-synthesizing respiratory state) and increased cytochrome content implies increased ATP-synthesizing capacity, since state 3 respiration is definitionally the ATP-synthesis-coupled respiratory state, but ATP yield itself was not directly assayed in that study.

Mechanism

Indirect inference only, from state 3 (ADP-stimulated) respiration rate and CPT2 fatty-acid-oxidation pathway activation to ATP synthesis capacity; not directly observed in any source located in this review.

Counter-evidence held on record

This entry shares its entire evidentiary basis with Mitochondrial burden above and adds no independently confirmed direct ATP data of its own; see the Overlap map. A future revision with a working PubMed abstract or Crossref channel should re-search specifically for a direct ATP-content assay in imipramine-exposed tissue, which this review's search-listing-only access could not rule out with full confidence.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met. A PubMed search for imipramine combined with hemoglobin, hematocrit, or oxygen saturation returned 22 results across the first page reviewed; none measured red-cell oxygen-carrying parameters as an outcome of imipramine treatment (the visible results were incidental mentions of imipramine in papers about unrelated topics, such as hemoglobin-derived peptides, dialysis, or blood-dyscrasia studies of other drugs). The FDA label's hematologic adverse-reaction list for imipramine (bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia) does not include anemia, a genuine null finding recorded here. No study parallel to the drug-specific arterial-oxygenation finding located for nortriptyline in obstructive sleep apnea (batch B007) was found for imipramine; a targeted search for imipramine and hypoxia or ischemia protection could not be completed because the query hit a PubMed bot-verification challenge and was not resolved within this review's available access (see tooling disclosure). No mitochondrial permeability transition pore screening study was found to include imipramine; the one such screen located and read directly in this review (Zhang et al, Stroke 2008) is confirmed, from its own reconstructed abstract, to have tested only nortriptyline, not imipramine, resolving another specific question from this dossier's brief.

Tooling disclosure

The hemoglobin/hematocrit/oxygen-saturation PubMed query returned a genuine, readable, non-error result set, so the core finding for that specific search is assessed as a real gap rather than a tooling failure. However, the follow-up hypoxia/ischemia query was blocked by a PubMed bot-verification challenge before it could be read, and the Europe PMC REST API, Crossref API, and Semantic Scholar API were each rate-limited (HTTP 429) on the attempts made in this review, so a channel that might have surfaced a direct imipramine oxygen-delivery study could not be fully exhausted. This session's general WebSearch tool was unavailable for the entire research phase of this dossier (budget exhausted, 200 of 200 calls used, by earlier work in this session), which narrowed this review to WebFetch-based channels only. A future revision with working WebSearch access, or working access to the blocked APIs, should re-run this category specifically before it is treated as a settled gap.